Compare · ADXS vs EYEG
ADXS vs EYEG
Side-by-side comparison of Advaxis, Inc. (ADXS) and Eyegate Pharmaceuticals, Inc. (EYEG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADXS and EYEG operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- EYEG has more recent analyst coverage (1 ratings vs 0 for ADXS).
- Company
- Advaxis, Inc.
- Eyegate Pharmaceuticals, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 1
Advaxis, Inc.
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Eyegate Pharmaceuticals, Inc.
EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.
Latest ADXS
- OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
- Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
- SEC Form 15-12G filed by Advaxis, Inc.
- SEC Form 10-K/A filed by Advaxis, Inc. (Amendment)
- Advaxis, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 10-K filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
- SEC Form S-8 POS filed by Advaxis, Inc.
Latest EYEG
- AllianceBernstein Launches Five New Active ETFs
- SEC Form 10-Q filed by Eyegate Pharmaceuticals, Inc.
- SEC Form 4 filed by Daniels Eric Joseph
- SEC Form 3 filed by new insider Daniels Eric Joseph
- Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy
- SEC Form D filed by Eyegate Pharmaceuticals, Inc.
- SEC Form 4: From Stephen covered exercise/tax liability with 250 shares, decreasing direct ownership by 0.36% to 68,292 units
- SEC Form 4: Mann Brenda covered exercise/tax liability with 62 shares, decreasing direct ownership by 0.41% to 15,136 units
- SEC Form 4: Romano Sarah covered exercise/tax liability with 83 shares, decreasing direct ownership by 0.36% to 23,059 units